

## Evaluation of a Tetracycline-Inducible Promoter in *Staphylococcus aureus* In Vitro and In Vivo and Its Application in Demonstrating the Role of *sigB* in Microcolony Formation

B. T. BATEMAN, N. P. DONEGAN, T. M. JARRY, M. PALMA, AND A. L. CHEUNG\*

Department of Microbiology and Immunology, Dartmouth Medical School, Hanover, New Hampshire 03755

Received 2 July 2001/Returned for modification 13 August 2001/Accepted 30 August 2001

**An inducible promoter system provides a powerful tool for studying the genetic basis for virulence. A variety of inducible systems have been used in other organisms, including pXyl-*xylR*-inducible promoter, the pSpac-*lacI* system, and the arabinose-inducible P<sub>BAD</sub> promoter, but each of these systems has limitations in its application to *Staphylococcus aureus*. In this study, we demonstrated the efficacy of a tetracycline-inducible promoter system in inducing gene expression in *S. aureus* in vitro and inside epithelial cells as well as in an animal model of infection. Using the *xyl/tetO* promoter::*gfp*<sub>uvr</sub> fusion carried on a shuttle plasmid, we demonstrated that dose-dependent tetracycline induction, as measured by bacterial fluorescence, occurred in each of the above environments while basal activation under noninduced conditions remained low. To ascertain how the system can be used to elucidate the genetic basis of a pathogenic phenotype, we cloned the *sigB* gene downstream of the inducible promoter. Induction of SigB expression led to dose-dependent attachment of the tested strain to polystyrene microtiter wells. Additionally, bacterial microcolony formation, an event preceding mature biofilm formation, also increased with tetracycline induction of SigB.**

*Staphylococcus aureus* is an important human pathogen that causes a variety of serious infections, including pneumonia, endocarditis, and sepsis (2). The recent emergence of vancomycin-resistant *S. aureus* strains has highlighted the need to identify potential targets for the development of novel antimicrobial therapies. Prime among these are virulence factors that contribute to pathogenesis. The evaluation of virulence genes in *S. aureus* has traditionally been conducted via gene knockout methods followed by complementation, often with a multicopy plasmid that overexpresses the gene product constitutively. An improvement to this method for assaying gene function is to induce gene expression with an inducible promoter system. Using such a system, gene expression can be titrated and the corresponding phenotype analyzed. Accordingly, more quantitative data on the role of a particular gene product in pathogenesis can be obtained.

A number of inducible promoter systems have been considered for use in *S. aureus*. These include the pXyl-*xylR*-inducible promoter (13) and the pSpac-*lacI* system (21) in *Bacillus subtilis* and the arabinose-inducible P<sub>BAD</sub> promoter from *Escherichia coli* (8). In exploring these promoters as tools to evaluate pathogenesis in *S. aureus*, each of these systems displayed major deficiencies that prevented their deployment. For instance, the xylose-inducible promoter system is repressible by glucose, a common constituent inside mammalian cells, thus prohibiting its use in in vivo studies. This repression cannot be readily relieved by a higher concentration of xylose, even in medium with low glucose concentration (unpublished data). The pSpac/*lacI* system was also not readily adaptable to *S. aureus* due, in part, to its high basal promoter activity (unpub-

lished data). Additionally, induction with IPTG (isopropylthiogalactopyranoside) for the pSpac promoter renders this system less attractive in an animal model system. Finally, the arabinose-inducible P<sub>BAD</sub> promoter has not been proven useful in *S. aureus*, probably due to poor penetration of arabinose into staphylococci.

The tetracycline-inducible promoter system, first described in *E. coli* and *B. subtilis* (7), was recently adapted to *S. aureus* (11, 22). This system appears to be useful for investigating the contribution of virulence genes to *S. aureus* pathogenesis both in vitro and in vivo. Using the reporter gene *gfp*<sub>uvr</sub> cloned downstream of the *xyl/tetO* promoter, we report here successful and dose-dependent tetracycline induction in three different experimental conditions, including in vitro growth, bacteria within epithelial cells, and a murine airpouch model. With this expression system, we also demonstrated the role of the alternative transcription factor  $\sigma^B$  (14, 20) in mediating microcolony formation, a prerequisite step for mature biofilm formation. Taken together, these data suggest that the tetracycline-inducible promoter system is a powerful tool, both in vitro and in vivo, for investigating the contribution of virulence genes in the pathogenesis of *S. aureus* infections.

### MATERIALS AND METHODS

**Bacterial strains, plasmids, and growth medium.** The bacterial strains and plasmids used in this study are listed in Table 1. TSB (tryptic soy broth) was used to grow *S. aureus* strains, while LB (Luria-Bertani) was used for *E. coli*. Chloramphenicol was used at 10  $\mu\text{g/ml}$  and ampicillin at 50  $\mu\text{g/ml}$ .

**Genetic manipulations in *E. coli* and *S. aureus*.** All restriction enzymes were acquired from Gibco-BRL Scientific (Coon Rapids, Minn.). An 800-bp fragment comprising the *tetR* gene (encoding the TetR repressor) and the *xyl/tetO* promoter was cleaved from pWH353 (7) and cloned into the *Pst*I and *Sma*I sites of shuttle plasmid pSK236. Correct insertion into the recombinant plasmid was confirmed by restriction mapping and sequencing. This construct was designated pALC2073.

To test the activity of the inducible promoter system, we constructed a plasmid in which the inducible *xyl/tetO* promoter drives the expression of the green

\* Corresponding author. Mailing address: Department of Microbiology, Dartmouth Medical School, Hanover, NH 03755. Phone: (603) 650-1340. Fax: (603) 650-1362. E-mail: ambrose.cheung@dartmouth.edu.

TABLE 1. Strains and plasmids used in this study

Strain or plasmid	Reference	Description
<i>S. aureus</i>		
RN6390	17	Laboratory strain that maintains its hemolytic pattern when propagated on sheep erythrocytes and has a genetic background similar to that of 8325-4
RN4220	17	Mutant of 8325-4 that accepts foreign DNA
ALC1001	3	<i>sigB</i> mutant of RN6390
ALC1497	3	ALC1001 complemented with shuttle plasmid pALC1496 (with the <i>sigB</i> gene)
ALC2158	This study	RN6390 containing pALC2073
ALC2085	This study	RN6390 containing pALC2084 (pALC2073:: <i>gfp<sub>uvr</sub></i> )
ALC2109	This study	RN6390 containing pALC2073:: <i>sigB</i>
<i>E. coli</i>		
XL-1 Blue		Cloning strain
TOP10F'	Invitrogen	Strain for cloning PCR fragments
Plasmids		
pCR2.1	Invitrogen	PCR cloning vector
pSK236	6	<i>S. aureus</i> - <i>E. coli</i> shuttle vector with pUC19 cloned into the <i>Hind</i> III site of pC194
pWH353	7	Plasmid carrying an 800-bp fragment comprising the <i>tetR</i> gene (encoding the TetR repressor) and the <i>xyl/tetO</i> promoter
pALC2073	This study	pSK236 containing the <i>tetR</i> gene and the <i>xyl/tetO</i> promoter that were cleaved from pWH353 and cloned into the <i>Pst</i> I and <i>Sma</i> I sites
pALC2084	This study	pALC2073 with <i>gfp<sub>uvr</sub></i> cloned into the <i>Eco</i> RI site
pALC2109	This study	pALC2073 with <i>sigB</i> cloned into the <i>Eco</i> RI site

fluorescent protein gene, *gfp<sub>uvr</sub>*. The *gfp<sub>uvr</sub>* gene was constructed by introducing an S65T mutation into *gfp<sub>uv</sub>* (Clontech, Palo Alto, Calif.), effecting a shift in the excitation maximum from 395 to 488 nm. This gene, *gfp<sub>uvr</sub>*, was cloned into the *Eco*RI site downstream from the inducible promoter in pALC2073. The correct insertion was determined by restriction mapping and sequencing. The recombinant plasmid was first electroporated into RN4220 and then finally into RN6390, as described (19).

To construct a plasmid containing *sigB* downstream from the inducible promoter, the *sigB* gene was first amplified by PCR using chromosomal DNA from strain RN6390 as the template. The following primer pairs were used for the amplification: 5'-GCTCTAGAGGGAGGTTTAAACATGGCGAAAGAGTCGAAATCAGCT-3' and 5'-ACGCGTCGACCTATTGATGTGCTGCTTCTTG-3', with the *Xba*I and *Sal*I sites in italic. The PCR product was ligated into pCR2.1 (Invitrogen, Carlsbad, Calif.). The *sigB* gene in pCR2.1 was cleaved and cloned downstream of the tetracycline-inducible promoter in pALC2073 at the *Eco*RI site. Correct orientation of the insert was confirmed by restriction mapping and sequencing. This plasmid was electroporated into RN4220 and then into RN6390 (19).

**Analysis of tetracycline-inducible promoter in vitro.** RN6390 containing pALC2073 (ALC2158) and pALC2084 (pALC2073::*gfp<sub>uvr</sub>*) (ALC2085) were grown overnight in TSB with chloramphenicol. The bacteria were then diluted 1:100 in TSB containing chloramphenicol and further cultured at 37°C with shaking (225 rpm) to an optical density at 650 nm (OD<sub>650</sub>) of 0.5. Tetracycline was then added at various concentrations (range, 0 to 500 ng/ml) that represented subinhibitory concentrations. The bacteria were sampled hourly (100 µl)

in triplicate and analyzed in microtiter wells for fluorescence and OD<sub>650</sub> simultaneously, using a multipurpose fluorescence spectrophotometer (FL600; BioTek Instruments, Winooski, Vt.). Results were reported as total fluorescence (FL) units/OD<sub>650</sub> unit to minimize the variation in fluorescence due to cell densities.

**Analysis of tetracycline-inducible promoter in CFT-1 epithelial cells.** CFT-1 cells, an immortalized cell line derived from the tracheal epithelial cells of a cystic fibrosis patient with a ΔF508 mutation in the CFTR gene, were grown on vitronectin-treated (Cohesion, Palo Alto, Calif.) coverslips (MatTek, Ashland, Mass.) at 37°C with 5% CO<sub>2</sub> until confluent. Cells were cultured in Dulbecco's modified Eagle's medium (DMEM)/F12 medium (Mediatech, Herndon, Va.) with 2 mM L-glutamine and 100 U of penicillin G, 100 µg of streptomycin, 250 ng of amphotericin B, 10% fetal bovine serum (FBS; Sigma, St. Louis, Mo.), 10 µg of insulin, 1 µM hydrocortisone, 3.75 µg of endothelial cell growth supplement, 25 ng of epidermal growth factor, 30 nM triiodothyronine, 5 µg of transferrin, and 10 ng of cholera toxin per ml (12). Prior to the assay, monolayers were washed three times with phosphate-buffered saline (PBS) and incubated for 1 h in DMEM/F12 plus 5 mM L-glutamine and 1% FBS.

ALC2085 from an overnight culture of TSB containing chloramphenicol was diluted 1:50 in similar medium and grown to OD<sub>650</sub> of 0.6. These bacteria were washed twice in PBS, passed through a 5-µm filter to remove cellular aggregates, and finally resuspended in PBS. Bacteria were added to CFT-1 cells at a multiplicity of infection (MOI) of 10:1 (bacteria-host cell ratio) and incubated for 2 h at 37°C and 5% CO<sub>2</sub>. Monolayers were then washed three times with PBS to remove unattached bacteria and incubated for 4 h at 37°C with 5% CO<sub>2</sub> in medium containing 200 µg of gentamicin (Sigma) per ml to kill extracellular ALC2085 or gentamicin plus tetracycline to induce gene expression. Induction of GFP expressed by intracellular bacteria was observed with a Leica DM IRBE microscope (Leica Microsystems, Buffalo, N.Y.) using Hamamatsu camera controller C4742-95 (Bridgewater, N.J.) and OpenLab software (Improvision, Lexington, Mass.).

**Analysis of tetracycline-inducible promoter in murine airpouch model.** To assess the utility of the tetracycline-inducible promoter system in vivo, we employed a murine airpouch model in which ALC2085 was used to colonize or infect a subcutaneous airpouch. To create the airpouch, 5 ml of air in a 5-ml syringe was injected intradermally with a 26-gauge needle on the posterior side of the mouse. Three days later, the airpouch was reinforced by an additional injection of 2.5 ml of air into the same pocket. After 3 more days, 10<sup>8</sup> CFU of *S. aureus* strain ALC2085 (pALC2084) was inoculated into the airpouch. To induce gene expression, 100 µg of tetracycline was injected intraperitoneally immediately following infection and subsequently every 12 h for 48 h. This amount of tetracycline has been titrated for expression in pilot studies. PBS injection was used as the control. Twelve hours after the last tetracycline injection, the airpouch was lavaged with 1 ml of PBS (pH 7.4). The aspirant was then diluted 1:100 in sterile PBS and analyzed for the population of fluorescent bacteria with a FACScan (Becton Dickinson, Franklin Lakes, N.J.).

**Preparation of cell extracts for SigB detection by Western blot.** RN6390, carrying the plasmid containing the tetracycline-inducible promoter that drives the expression of *sigB* (ALC2109) and the vector control (ALC2158), was grown in a 25-ml culture overnight in various concentrations of tetracycline. Following pelleting, the cells were resuspended in 1 ml of TEG buffer (25 mM Tris, 5 mM EGTA, pH 8), and cell extracts were prepared using lysostaphin (AMBI, Purchase, N.Y.) as described (4). Cell extracts were then calibrated for total cellular proteins, and 50 µg of each sample was loaded on a sodium dodecyl sulfate-12% polyacrylamide gel electrophoresis (SDS-PAGE) gel, electrophoresed, and immunoblotted onto nitrocellulose as described (1).

To detect σ<sup>B</sup>, anti-σ<sup>B</sup> monoclonal antibody 1D1 diluted 1:1,000 was allowed to incubate with the immunoblot for 3 h. The blot was then washed and incubated with affinity-purified goat anti-mouse immunoglobulin antibody conjugated to alkaline phosphatase (Jackson ImmunoResearch, West Grove, Pa.) at a 1:10,000 dilution. Reactive bands were then detected with developing substrates as described (1). The intensities of the reactive bands were quantitated by densitometric analysis, using SigmaGel software (Jandel Scientific, San Rafael, Calif.).

**Microcolony formation and adherence assays.** *S. aureus* strains analyzed for bacterial aggregation and microcolony formation were inoculated in TSB and grown at 37°C to an OD<sub>650</sub> of 1.1. The bacteria were then diluted 1:100 in TSB with appropriate antibiotics (including increasing amounts of tetracycline when induction was desired), and 100 µl of each mixture was then added to the well of a polystyrene 96-well tissue culture plate (Corning, Corning, N.Y.). The bacteria were then grown at 37°C for 24 h without shaking. To assess microcolony formation, microscopy was used to examine intercellular aggregation upon induction of σ<sup>B</sup> with tetracycline, using the 10× objective of a Leica DM IRBE microscope.




FIG. 1. Induction of the *xyl/tetO* promoter linked to the *gfp<sub>uvr</sub>* reporter with increasing concentrations of tetracycline in strain ALC2085. Following overnight culture, the cells were diluted 1:100 in fresh TSB and then grown to an  $OD_{650}$  of 0.5. Tetracycline was then added to the final concentrations shown above. The cells were sampled hourly following induction (100  $\mu$ l each, in triplicate). Fluorescence and  $OD_{650}$  measurements were obtained using a multipurpose spectrophotometer (FL600; Biotek Instrument). Results are presented as reported fluorescence (FL) units/ $OD_{650}$  to account for variations in fluorescence due to cell density. Data are given as the mean of the triplicate measurements. Error bars are too small to be shown. The experiment was repeated twice, with one representative experiment shown.

To quantitate bacterial adherence, a prelude to mature biofilm formation, nonadherent bacteria from overnight cultures were removed from the microtiter wells with gentle suction. The wells were then washed three times with distilled water and air dried for 10 min. Attached bacteria were stained with 150  $\mu$ l of 0.04% safranin O solution (in 20% ethanol). Staining was allowed to proceed for 10 min, after which the plate was washed four times with water and dried. For quantitation, 100  $\mu$ l of 30% acetic acid was added to each well to dissolve the stain. The  $OD_{405}$  of the dissolved stain was then measured in a multipurpose enzyme-linked immunosorbent assay (ELISA) reader (FL600).




FIG. 2. Tetracycline-induced GFP expression of ALC2085 inside CFT-1 epithelial cells. ALC2085, grown to an  $OD_{650}$  of 0.6, was added to CFT-1 monolayers at an MOI of 10:1 for 2 h. Extracellular bacteria were removed by washing followed by the addition of gentamicin (200  $\mu$ g/ml) for 4 h to kill any remaining extracellular microorganisms. Tetracycline was added to some wells to facilitate induction. Cells were then examined by fluorescence microscopy. Most of the bacteria were intracellular, as evidenced by the failure of these bacteria to stain with anti-protein A antibody conjugated to Texas Red (data not shown). The experiment was repeated twice, with one representative experiment shown. Upon tetracycline induction of the *xyl/tetO* promoter of intracellular bacteria driving the expression of GFP, green fluorescence was observed only in tissue culture wells containing tetracycline.

## RESULTS

**Functionality of tetracycline-inducible promoter in vitro.** To test the inducible promoter in vitro and to ascertain the optimal concentration of tetracycline for induction, we used the *gfp<sub>uvr</sub>* reporter gene that we have cloned downstream of the inducible promoter in recombinant shuttle plasmid pALC2058. The promoter activity in strain RN6390 was then analyzed by measuring bacterial fluorescence as an indicator of GFP<sub>uvr</sub> expression. Our data revealed dose-dependant induction of the *xyl/tetO* promoter, with maximum induction at a tetracycline concentration of 250 ng/ml (Fig. 1). At tetracycline concentrations exceeding this value (e.g., 500 ng/ml), growth retardation occurred, corresponding to a decrease in promoter activity due to lower cell number. Importantly, we were not able to detect the activity of the promoter under noninduced conditions during the entire time course of this experiment (5 h), as indicated by the relatively flat FL/ $OD_{650}$  response of ALC2085 in the absence of tetracycline, similar to RN6390 containing the vector control when grown under identical conditions (data not shown).

**Functionality of inducible promoter inside CFT-1 epithelial cells.** To determine the tetracycline inducibility of the *xyl/tetO* promoter of pALC2084 inside epithelial cells, we incubated *S. aureus* strain ALC2085 (RN6390 with pALC2084) with CFT-1 cells (see Materials and Methods) followed by treatment with medium containing gentamicin (to kill extracellular *S. aureus*) in the presence and absence of tetracycline for 4 h. In previous studies, we have shown that internalization of live *S. aureus* by CFT-1 cells occurred efficiently with this method (12). Following internalization, monolayers of CFT-1 cells containing intracellular ALC2085 were examined by fluorescent microscopy for GFP expression. As shown in Fig. 2, tetracycline was accessible to the intracellular compartment containing ALC2085 and able to induce the expression of GFP at concentrations ranging from 125 to 250 ng/ml, while no GFP expression was detected in the absence of tetracycline.

**Functionality of inducible promoter in murine airpouch model.** To evaluate the utility of the tetracycline-inducible promoter in vivo, we employed a murine airpouch model. Following the creation of an airpouch, mice were infected with




FIG. 3. Flow cytometry of lavaged bacteria obtained from the murine airpouch. An airpouch was created on the posterior side of the mouse. ALC2085 (RN6390 with a plasmid carrying the inducible promoter driving *gfp<sub>uvr</sub>*) was injected into the airpouch at  $10^8$  CFU. Tetracycline (100  $\mu$ g) or a PBS injection was given every 12 h for 48 h. At 12 h after the final injection, the airpouch was lavaged with 1 ml of PBS. The aspirant was then diluted 1:1,000 in PBS (pH 7.4) and analyzed on a FACScan (Becton Dickinson). Ten thousand events were detected by forward scatter and a histogram was generated, showing the number of counts as a function of fluorescence. The experiment was repeated with two mice, with one representative experiment shown.

ALC2085 at  $10^8$  CFU. Subsequently, the mice were each given an IP injection of 100  $\mu$ g of tetracycline or PBS every 12 h for 48 h. The airpouch was lavaged 12 h after the last IP injection, and the lavage fluid was analyzed with a FACScan (Becton Dickinson). Ten thousand events were acquired for each sample and counts of detected events were plotted as a function of fluorescence. As shown in Fig. 3, a higher proportion of fluorescent bacteria were detected under the induced condition compared with the noninduced control.

**Employment of tetracycline-inducible system to demonstrate the role of  $\sigma^B$  in attachment and microcolony formation.** To demonstrate how the inducible promoter system might be used to explore the regulation of a pathogenic phenotype, we examined SigB under inducible conditions in an attempt to study its role in biofilm formation. For this purpose, we cloned a ribosome-binding site together with the coding region of *sigB* downstream of the inducible promoter in shuttle plasmid pALC2073. The recombinant plasmid pALC2109 was electroporated into RN4220 and then into RN6390 (see Materials and Methods), a strain that is partially deficient (not absent [unpublished data]) in  $\sigma^B$  expression due to an 11-bp deletion in *rsbU*.

To ensure that the RN6390 clone carrying pALC2109 was synthesizing  $\sigma^B$  in a dose-dependent manner upon induction, the strain was grown in various amounts of tetracycline in overnight cultures from which cell extracts were prepared, and 50  $\mu$ g of total protein from each extract was run on an SDS gel and immunoblotted. The blot was probed with 1D1 anti- $\sigma^B$  monoclonal antibody at a dilution of 1:1,000, followed by an appropriate conjugate and developing substrates. As shown in Fig. 4, the expression of  $\sigma^B$  correlated well with tetracycline induction in a dose-dependant fashion. Densitometric analysis revealed 719 densitometric units for the noninduced culture,

1,800 units for tetracycline induction at 50 ng/ml, and 3,297 units for induction at 150 ng/ml. As a control, we used RN6390 containing the vector pALC2073 alone (ALC2158). As anticipated from a SigB-deficient strain, SigB was also expressed from ALC2158, but the level of expression was low (556 densitometric units for the intact Sigma and 248 units for the degradative product); this level of expression was similar to that of ALC2109 without induction.

Having established the induction of  $\sigma^B$  expression by tetracycline in strain ALC2109, we proceeded to ascertain the effect of  $\sigma^B$  expression on staphylococcal attachment to microtiter wells, a simulated event that mirrors early biofilm formation in vitro (23). Bacterial attachment was assessed by staining with safranin the adherent colonies on the bottom of the microtiter wells with overnight cultures. The safranin stain was then solubilized by the addition of 30% acetic acid. The OD<sub>405</sub> for each well was then determined using a multipurpose spectrophotometer (FL600). As controls, we tested RN6390 ( $\sigma^B$  deficient), ALC1001 (RN6390 with a  $\sigma^B$  mutation), and ALC1497 (ALC1001 with a multicopy plasmid encoding the  $\sigma^B$  operon) (3).

Although both RN6390 and ALC1001 attached poorly, ALC1497, a strain that hyperexpresses  $\sigma^B$ , attached well. Interestingly, bacterial attachment of ALC2109 to microtiter wells was proportional to the induction of  $\sigma^B$  (Fig. 5 and 4), with maximal adherence occurring at a tetracycline concentration of 150 ng/ml. At higher concentrations, growth was inhibited under the nonshaking and oxygen-limiting conditions of microtiter wells.

To ensure that biofilm formation was attributable to  $\sigma^B$  induction and not a consequence of antibiotic stress, ALC2158 (RN6390 with pALC2073), a strain with just the inducible promoter, we also tested for biofilm formation after growth in




FIG. 4. Immunoblot of cell extracts of ALC2109 (RN6390 with a plasmid containing the inducible promoter driving *sigB*) and ALC2158 (RN6390 with the vector control) as detected by anti-SigB monoclonal antibody 1D1. The strain was grown overnight in TSB with the amount of tetracycline indicated. Cell extracts were prepared, and 50  $\mu$ g of total protein each was resolved by SDS-PAGE and blotted onto nitrocellulose. SigB protein was detected with anti-SigB monoclonal antibody 1D1 (1:1,000 dilution). The dose-dependent induction of SigB was confirmed by densitometry of the reactive bands (see text). The experiment was repeated twice, with one representative experiment shown.

medium containing various amounts of tetracycline (0 to 150 ng/ml). At all tetracycline concentrations, ALC2158 failed to produce biofilm above parental levels (data not shown).

It has been suggested that bacterial attachment and subsequent microcolony formation or bacterial aggregation pre-

cedes biofilm formation (23). Following overnight growth under identical conditions as for the attachment assay, we observed increasing microcolony formation as a result of bacterial aggregation by microscopy. As shown in Fig. 6, the size of the autoaggregates was proportional to the  $\sigma^B$  level attributable to tetracycline induction.

## DISCUSSION

In evaluating the genetic basis for virulence in *S. aureus*, there is a need for an inducible promoter system that can be employed both in vitro and in vivo. Using such a system, gene expression can be titrated and the corresponding phenotype analyzed, thereby providing insights into the pathogenesis of specific genes. We have previously attempted to deploy a number of inducible systems in *S. aureus*, including pXyl-*xylR*, pSpac-*lacI*, and P<sub>BAD</sub>, and found each of them to have major deficiencies. In contrast, the tetracycline-inducible system, consisting of the *tetR* gene (encoding the TetR repressor) and the *xyl/tetO* promoter, has proven to be highly useful for evaluating *S. aureus* gene expression in vitro and in vivo, including those found in cultured epithelial cells and in an animal model of infection.

The tetracycline-inducible promoter system possesses several characteristics that make it ideally suited for genetic studies in *S. aureus*. First, the basal level of expression of the promoter is extremely low, as evidenced by the failure of the strain carrying the inducible promoter-*gfp<sub>uvr</sub>* construct to fluoresce above background levels under noninducing conditions.




FIG. 5. Bacterial attachment to polystyrene microtiter wells. Cells were grown in TSB for 24 h in a 96-well polystyrene tissue culture plate. The plate was then washed three times gently with distilled water. The wells were stained with safranin O for 10 min, washed, and air dried. Then 100  $\mu$ l of 30% acetic acid was added to each well to solubilize the stain. The OD<sub>405</sub> for each well was then determined. Each of the conditions was replicated in eight wells. The mean OD<sub>405</sub> values for each condition are displayed, with the error bar showing the standard deviation from the mean.




FIG. 6. Microcolony formation with various levels of  $\sigma^B$  induction in response to increasing tetracycline concentrations. Strains were grown in a 96-well polystyrene tissue culture plate under the same conditions used in the attachment assay (see Materials and Methods). Microscopy was done at 10 $\times$  magnification. Strain RN6390 disclosed a very low level of intercellular aggregation, while the isogenic *sigB* mutant ALC1001 did not exhibit any tendency toward cellular aggregation. Upon induction of  $\sigma^B$  expression by increasing concentrations of tetracycline, intercellular aggregation, as reflected by the size of the microcolony, was found to increase.

This finding allows meaningful comparison of phenotypes under induced and noninduced conditions while avoiding the problem of leaky expression at basal levels. Second, induction is dose dependent (Fig. 1), making it possible to titrate gene expression to wild-type levels. This system clearly represents an advance in the induction of gene expression over a multicopy plasmid that provides constitutive and, at times, uncontrollable expression. Third, a high level of promoter activity, if required, can be achieved with this system, as evidenced by the high level of GFP<sub>uvr</sub> production with the GFP reporter (Fig. 1), as well as by augmented  $\sigma^B$  expression achieved with the inducible promoter-*sigB* fusion (Fig. 4).

Besides in vitro studies, this inducible promoter system has proven to be useful for studies of *S. aureus* inside epithelial cells. There is now substantial evidence that *S. aureus* is internalized into human epithelial cells as well as cultured osteoblasts (9, 10, 15, 16). Indeed, it was recently shown that *S. aureus* is not an innocent bystander during the internalization process by a pulmonary epithelial cell line, but rather replicates and induces apoptosis in host cells (12). Given that *S. aureus*, as an adaptive intracellular pathogen inside epithelial cells, may contribute toward chronicity in human infections (e.g., osteomyelitis and chronic abscesses), it will be essential to identify the *S. aureus* genes that facilitate this pathogenic process.

We argue that the tetracycline-inducible promoter can be a powerful tool for this purpose, because high levels of gene induction were achievable in internalized *S. aureus* cells (inside CFT-1 epithelial cells), while basal promoter activity was undetectable in the absence of tetracycline (Fig. 2). In addition to cell cultures, we were able to show that high levels of promoter activity can be induced in a murine airpouch model, while the promoter remained quiescent under noninduced conditions. We thus propose that this promoter system can be useful in

ascertaining the role of various pathogenic genes in cultured epithelial cells as well as in animal models of infections.

As a demonstration of how the inducible promoter can be used to probe the regulation of a pathogenic phenotype, we examined the role of  $\sigma^B$  in two key components of biofilm formation, attachment and microcolony formation. Biofilms are purported to play a role in the pathogenesis of persistent infections, presumably by minimizing the exposure of the bacteria to antimicrobial agents and the host defenses (5). It has been suggested that two antecedent but distinct events leading to mature biofilm formation are attachment and intercellular aggregation (23). By placing *sigB* under the control of the inducible promoter on a shuttle plasmid in RN6390, we were able to achieve titratable  $\sigma^B$  expression. We found, as have others (18), that the presence of  $\sigma^B$  correlated with increased attachment to polystyrene. More specifically, we have found that increasing expression of SigB (Fig. 4) in response to tetracycline induction correlated with higher levels of bacterial attachment to the polystyrene surface. Whether attachment of staphylococcal cells to polystyrene directly mimics the early step in mature biofilm formation is not clear. Further experiments have to be done to demonstrate if  $\sigma^B$  plays a role in regulating attachment to relevant biological surfaces (catheters in vivo, biological tissues, etc.).

A second step in biofilm formation, recognized previously in *Staphylococcus epidermidis*, is microcolony formation or intercellular aggregation (23). By microscopy, we were able to demonstrate that increased  $\sigma^B$  induction correlated with the size of bacterial autoaggregates of *S. aureus* grown in liquid medium. Whether *S. aureus* can produce  $\sigma^B$  to a high enough level to mediate autoaggregation in vivo, as found in our in vitro studies, is not clear. Further studies are therefore needed to ascertain the significance of *S. aureus* microcolony formation in vivo.

## ACKNOWLEDGMENTS

We thank George O'Toole for assistance with fluorescence microscopy and Susham Ingavale for critically evaluating the manuscript. This work was supported in part by NIH grant AI47441 to A.L.C.

## REFERENCES

1. Blake, M. S., K. H. Johnston, G. J. Russell-Jones, and E. C. Gotschlich. 1984. A rapid sensitive method for detection of alkaline phosphatase-conjugated anti-antibody on Western blots. *Anal. Biochem.* **136**:175–179.
2. Boyce, J. M. 1997. Epidemiology and prevention of nosocomial infections, p. 309–329. In K. B. Crossley and G. L. Archer (ed.), *The staphylococci in human disease*. Churchill Livingstone, New York, N.Y.
3. Cheung, A. L., Y. T. Chien, and A. S. Bayer. 1999. Hyperproduction of alpha-hemolysin in a *sigB* mutant is associated with elevated SarA expression in *Staphylococcus aureus*. *Infect. Immun.* **67**:1331–1337.
4. Chien, Y., and A. L. Cheung. 1998. Molecular interactions between two global regulators. *sar* and *agr*, in *Staphylococcus aureus*. *J. Biol. Chem.* **274**:2645–2652.
5. Costerton, J. W., P. S. Stewart, and E. P. Greenberg. 1999. Bacterial biofilms: a common cause of persistent infections. *Science* **284**:1318–1322.
6. Gaskill, M. E., and S. A. Khan. 1988. Regulation of the enterotoxin B gene in *Staphylococcus aureus*. *J. Biol. Chem.* **263**:6276–6280.
7. Geissendoerfer, M., and W. Hillen. 1990. Regulated expression of heterologous genes in *Bacillus subtilis* using the Tn10 encoded *tet* regulatory elements. *Appl. Microbiol. Biotechnol.* **33**:657–663.
8. Guzman, L., D. Belin, M. Carson, and J. Beckwith. 1995. Tight regulation, modulation, and high-level expression by vectors containing the arabinose P<sub>BAD</sub> promoter. *J. Bacteriol.* **177**:4121–4130.
9. Hamill, R. J., J. M. Vann, and R. A. Proctor. 1986. Phagocytosis of *Staphylococcus aureus* by cultured bovine aortic endothelial cells: model for post-adherence events in endovascular infections. *Infect. Immun.* **54**:833–836.
10. Hudson, M. C., W. K. Ramp, N. C. Nicholson, A. S. Williams, and M. T. Nousiainen. 1995. Internalization of *Staphylococcus aureus* by culture osteoblasts. *Microb. Pathog.* **19**:409–419.
11. Ji, Y., A. Marra, M. Rosenberg, and G. Woodnut. 1999. Regulated antisense RNA eliminates alpha-toxin virulence in *Staphylococcus aureus* infection. *J. Bacteriol.* **181**:6585–6590.
12. Kahl, B. C., M. Goulian, W. van Wamel, M. Herrmann, S. M. Simon, G. Kaplan, G. Peters, and A. L. Cheung. 2000. *Staphylococcus aureus* RN6390 replicates and induces apoptosis in a pulmonary epithelial cell line. *Infect. Immun.* **68**:5385–5392.
13. Kim, L., A. Mogk, and W. Schumann. 1996. A xylose-inducible *Bacillus subtilis* integration vector and its application. *Gene* **181**:71–76.
14. Kullik, I., P. Giachino, and T. Fuchs. 1998. Deletion of alternative sigma factor  $\sigma^B$  in *Staphylococcus aureus* reveals its function as a global regulator of virulence genes. *J. Bacteriol.* **180**:4814–4820.
15. Lowy, F. 1998. *Staphylococcus aureus* infections. *N. Engl. J. Med.* **339**:520–532.
16. Lowy, F. D., J. Fant, L. L. Higgins, S. K. Ogawa, and V. B. Hatcher. 1988. *Staphylococcus aureus*-human endothelial cells interactions. *J. Ultrastruct. Mol. Struct. Res.* **98**:137–146.
17. Novick, R. P. 1990. The staphylococcus as a molecular genetic system, p. 1–40. In R. P. Novick (ed.), *Molecular biology of the staphylococci*. VCH Publishers, New York, N.Y.
18. Rachid, S., K. Ohlsen, U. Wallner, J. Hacker, M. Hecker, and W. Ziebuhr. 2000. Alternative transcription factor  $\sigma^B$  is involved in regulation of biofilm expression in a *Staphylococcus aureus* mucosal isolate. *J. Bacteriol.* **182**:6824–6826.
19. Schenk, S., and R. A. Laddaga. 1992. Improved method for electroporation of *Staphylococcus aureus*. *FEMS Microbiol. Lett.* **73**:133–138.
20. Wu, S., H. de Lencastre, and A. Tomasz. 1996. Sigma-B, a putative operon encoding alternate sigma factor of *Staphylococcus aureus* RNA polymerase: molecular cloning and DNA sequencing. *J. Bacteriol.* **178**:6036–6042.
21. Yansura, D., and D. J. Henner. 1984. Use of the *Escherichia coli lac* repressor and operator to control gene expression in *Bacillus subtilis*. *Proc. Natl. Acad. Sci. USA* **81**:439–443.
22. Zhang, L., F. Fan, L. M. Palmer, M. A. Lonetto, C. Petit, L. L. Voelker, A. St. John, B. Bankosky, M. Rosenberg, and D. McDevitt. 2000. Regulated gene expression in *Staphylococcus aureus* for identifying conditional lethal phenotypes and antibiotic mode of action. *Gene* **255**:297–305.
23. Ziebuhr, W., C. Heilmann, F. Gotz, P. Meyer, K. Wilms, E. Straube, and J. Hacker. 1997. Detection of the intercellular adhesion gene cluster (*ica*) and phase variation in *Staphylococcus epidermidis* blood culture strains and mucosal isolate. *Infect. Immun.* **60**:890–896.

Editor: E. I. Tuomanen